Tudor Investment Corp
CPRX

Tudor Investment Corp’s Catalyst Pharmaceutical CPRX Stock Holding History

Tudor Investment Corp’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,395
Closed -$505K – 3667
2026
Q1 		$505K Buy
+20,395
New +$486K ﹤0.01% 2812
2025
Q3 		– Sell
-76,088
Closed -$1.65M – 3434
2025
Q2 		$1.65M Buy
76,088
+14,502
+24% +$342K ﹤0.01% 1800
2025
Q1 		$1.49M Buy
61,586
+2,034
+3% +$45.8K 0.01% 1547
2024
Q4 		$1.24M Buy
+59,552
New +$1.28M ﹤0.01% 1574
2022
Q4 		– Sell
-73,965
Closed -$949K – 2461
2022
Q3 		$949K Buy
+73,965
New +$877K 0.02% 946

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tudor Investment Corp's CPRX Position: Q2 2026 in Review

Tudor Investment Corp sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 20,395 shares — an estimated $505K sold.

Tudor Investment Corp first reported a position in CPRX in Q3 2022 and held it in 5 quarters. The position peaked at $1.65M in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Tudor Investment Corp reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 20,395 Catalyst Pharmaceutical shares in Q2 2026, an estimated $505K.
  • Tudor Investment Corp first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 5 quarters.
  • Tudor Investment Corp's Catalyst Pharmaceutical position peaked at $1.65M in Q2 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.